Why the study?
Does ticlopidine reduce the occurrence of stroke, myocardial infarction, or vascular death in patients with recent cerebral ischemia?
Population
Patients of both sexes who have had recent cerebral ischemia
Design
Review
Authors
Loading...
May support ticlopidine post-cerebral ischemia with neutropenia monitoring; leaves open randomized confirmation.
Does ticlopidine reduce the occurrence of stroke, myocardial infarction, or vascular death in patients with recent cerebral ischemia?
Ticlopidine is a promising antiplatelet agent for reducing major vascular events in patients with recent cerebral ischemia, though monitoring for neutropenia is required.
Robert et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: